Bayer guided for lower earnings this year as it continues to work through a turnaround plan, but said performance is expected ...

While Bayer’s consumer and crop science divisions continued to slide—both in the fourth quarter and in 2024 overall—the ...

Bayer reported Q4 adjusted EPS of $0.28, missing estimates, but sales beat forecasts. The company sees 2025 as a tough year, with growth expected from 2026.

DelveInsight's Interferons Market Insights report provides the current and forecast market analysis, individual leading ...

The increasing occurrence of chronic and infectious diseases is the main driver of the rising demand for interferon. Furthermore, advancements in interferon production and ongoing research and ...